Experts address challenges in CGT commercialization

download Read more
Roundtable Report

Roundtable report: Keeping Pace with CGT Innovation - Clinical, Regulatory & Commercial Considerations

The future is bright for cell and gene therapies (CGTs), driven by recent successes and technological advances as they broaden into areas such as autoimmune, neurodegenerative and cardiovascular diseases. However, overcoming scalability challenges is vital for achieving long-term commercialization growth.

In parallel to the 2024 Meeting on the Mesa in Arizona, ICON and Citeline met with industry experts to discuss the commercial challenges facing CGTs and outline the key strategies for long-term success, including:

  • Challenges in clinical development
  • Impact of automation and AI on manufacturing
  • Importance of early and ongoing regulatory engagement
  • Financial viability and payer reimbursement
  • Collaboration with academia, biotech and pharma to enhance efficiency

Simply complete the form
to download your free report.

By ticking this box, you agree to receive emails from Citeline, and carefully selected partners
You agree Citeline and ICON may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and ICON.
Pharma Ignite Inspire. Connect. Innovate.
Powered by
Scrip Medtech Insight In Vivo HBW Insight Generics Bulletin Pink Sheet

Copyright ©️ 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.